Evidence map›Paper›PMID 34411313›Full record

ArticleClinical and experimental dermatology2022

Patient characteristics in tardive COVID-19 pseudoperniosis: a case series of 16 patients.

B Ganatra, R Amarnani, Y Alfallouji, K Dear, E Twigg, J P Westwood, B Goulden, V Morris, T Hillman, S Goolamali and 6 more

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

B GanatraDepartment of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK.
R AmarnaniDepartment of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK.
Y AlfalloujiDepartment of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK.
K DearDepartment of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK.
E TwiggDepartment of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK.
J P WestwoodDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
B GouldenDepartment of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.
V MorrisDepartment of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.
T HillmanDepartment of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
S GoolamaliDepartment of Dermatology, King's College Hospital NHS Foundation Trust, London, UK.
Z NaderiDepartment of Dermatology, West Hertfordshire Hospitals NHS Trust, Reading, UK.
R SidwellDepartment of Dermatology, West Hertfordshire Hospitals NHS Trust, Reading, UK.
P ElleryDepartment of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK.
E CalonjeDepartment of Histopathology, St John's Institute of Dermatology, London, UK.
G KravvasDepartment of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-1924-0149
C B BunkerDepartment of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-6693-7483
University College London Hospitals NHS Foundation Trust · GBWest Hertfordshire Hospitals NHS Trust · GBKing's College Hospital NHS Foundation Trust · GBSt John's Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute pseudoperniosis (PP) has a recognized association with COVID-19 and tends to occur without cold precipitation in young, healthy patients, often without a clear history of COVID-19. These lesions usually resolve within 2 weeks and without long-term sequelae. In the early months of 2021, patients with delayed and protracted PP began to emerge. We have called this presentation 'tardive COVID-19 PP (TCPP)'.

aimTo consolidate and expand knowledge on TCPP, we describe the clinical characteristics, treatments and outcomes of 16 patients with TCPP who were reviewed by our outpatient dermatology service.

resultsThe initial clinical manifestations were erythema, swelling and PP of the fingers in 56.2%, and of the toes in 31.2%, desquamation in 56.2% and acrocyanosis in 12.5%. Ten patients had eventual involvement of all acral sites. The median duration of symptoms was 191 days. Six patients reported close contact with a confirmed or suspected case of COVID-19, but only two had positive COVID-19 tests. Four patients experienced complete or almost complete resolution of symptoms, while the rest remain under active treatment.

conclusionUnlike acute PP, TCPP has a protracted and delayed presentation that is typically associated with profound acrocyanosis. Patients with TCPP represent a new phenomenon that is part of the post-COVID-19 syndrome, with risk factors and pathophysiology that are not yet fully understood. Our data indicate that likely predisposing factors for developing TCPP include young age, a preceding history of cold intolerance and an arachnodactyloid phenotype. Anorexia, connective tissue disorders or sickle cell trait may also predispose to TCPP. In addition, low titre antinuclear antibody positivity, the presence of cryoglobulins, or low complement levels may represent further risk factors. Finally, prolonged low temperatures are also likely to be contributing to the symptoms.

Indexed as

Acute DiseaseAdolescentAdultAgedChilblainsCohort StudiesCOVID-19FemaleFoot DermatosesHand DermatosesHumansMaleMiddle AgedPost-Acute COVID-19 SyndromeTime FactorsYoung Adult

Identifiers

PMID34411313
PMCPMC8444777
OpenAlexW3195696709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.